113.74
Rhythm Pharmaceuticals Inc stock is traded at $113.74, with a volume of 728.53K.
It is down -0.02% in the last 24 hours and up +14.87% over the past month.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.
See More
Previous Close:
$113.76
Open:
$112.76
24h Volume:
728.53K
Relative Volume:
1.21
Market Cap:
$7.55B
Revenue:
$136.86M
Net Income/Loss:
$-168.69M
P/E Ratio:
-40.48
EPS:
-2.81
Net Cash Flow:
$-113.49M
1W Performance:
+1.96%
1M Performance:
+14.87%
6M Performance:
+77.69%
1Y Performance:
+132.08%
Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile
Name
Rhythm Pharmaceuticals Inc
Sector
Industry
Phone
857-264-4280
Address
222 BERKELEY STREET, BOSTON, MA
Compare RYTM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
RYTM
Rhythm Pharmaceuticals Inc
|
113.74 | 7.56B | 136.86M | -168.69M | -113.49M | -2.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-25 | Initiated | Goldman | Buy |
| Jul-07-25 | Initiated | Leerink Partners | Outperform |
| Apr-07-25 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-05-25 | Resumed | Stifel | Buy |
| Jan-02-25 | Initiated | Jefferies | Buy |
| Dec-20-24 | Initiated | Oppenheimer | Outperform |
| Oct-21-24 | Initiated | Guggenheim | Buy |
| Sep-18-24 | Initiated | H.C. Wainwright | Buy |
| Sep-17-24 | Initiated | JMP Securities | Mkt Outperform |
| May-08-24 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-19-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-01-23 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-18-23 | Resumed | Canaccord Genuity | Buy |
| Aug-08-22 | Upgrade | Goldman | Neutral → Buy |
| Aug-05-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-17-22 | Reiterated | Needham | Buy |
| Mar-02-22 | Resumed | Stifel | Buy |
| Feb-17-22 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-14-21 | Resumed | Goldman | Neutral |
| Aug-04-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Aug-04-21 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Nov-30-20 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-08-20 | Initiated | Goldman | Sell |
| Jul-12-19 | Upgrade | Stifel | Hold → Buy |
| Jul-08-19 | Initiated | Canaccord Genuity | Buy |
| Mar-13-19 | Initiated | Ladenburg Thalmann | Buy |
| Sep-07-18 | Resumed | Morgan Stanley | Overweight |
| Jun-25-18 | Reiterated | Needham | Buy |
| Jun-15-18 | Reiterated | Needham | Buy |
| Oct-30-17 | Initiated | BofA/Merrill | Buy |
| Oct-30-17 | Initiated | Needham | Buy |
View All
Rhythm Pharmaceuticals Inc Stock (RYTM) Latest News
Rhythm Pharmaceuticals Q3 2025 Earnings Preview - MSN
Is it time to cut losses on Rhythm Pharmaceuticals Inc.Market Performance Report & Weekly Breakout Opportunity Watchlist - newser.com
Can Rhythm Pharmaceuticals Inc. stock weather global recessionWall Street Watch & Weekly Consistent Profit Watchlists - newser.com
Is Rhythm Pharmaceuticals Inc. (1RV) stock supported by free cash flowJuly 2025 Breakouts & Long Hold Capital Preservation Plans - newser.com
Can Rhythm Pharmaceuticals Inc. (1RV) stock hold up in economic slowdownCPI Data & Weekly Return Optimization Plans - newser.com
Visualizing Rhythm Pharmaceuticals Inc. stock with heatmapsPortfolio Performance Report & Pattern Based Trade Signal System - newser.com
Is a relief rally coming for Rhythm Pharmaceuticals Inc. holdersJuly 2025 Institutional & Consistent Profit Alerts - newser.com
How currency fluctuations impact Rhythm Pharmaceuticals Inc. stockWeekly Risk Summary & Safe Capital Growth Stock Tips - newser.com
How resilient is Rhythm Pharmaceuticals Inc. stock in market downturns2025 Big Picture & Long-Term Growth Stock Strategies - newser.com
Will Rhythm Pharmaceuticals Inc. price bounce be sustainableMarket Sentiment Summary & AI Optimized Trading Strategy Guides - newser.com
Can machine learning forecast Rhythm Pharmaceuticals Inc. recoveryMarket Risk Analysis & Low Risk Investment Opportunities - newser.com
Published on: 2025-11-02 22:26:41 - newser.com
Is Rhythm Pharmaceuticals Inc. reversing from oversold territoryLayoff News & Free Long-Term Investment Growth Plans - newser.com
Is Rhythm Pharmaceuticals Inc. stock positioned for digital transformationGlobal Markets & Free High Return Stock Watch Alerts - newser.com
Rhythm Pharmaceuticals Hits New 52-Week High of $116.00 - Markets Mojo
Rhythm Pharmaceuticals, Inc. $RYTM Shares Sold by State of New Jersey Common Pension Fund D - MarketBeat
Will Rhythm Pharmaceuticals Inc. stock benefit from automation2025 Dividend Review & Community Driven Trade Alerts - newser.com
Rhythm Pharmaceuticals (NASDAQ:RYTM) Insider Sells $323,753.15 in Stock - MarketBeat
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Investors Are Less Pessimistic Than Expected - 富途牛牛
Rhythm Pharmaceuticals (NASDAQ:RYTM) Sets New 1-Year HighHere's What Happened - MarketBeat
Rhythm Pharmaceuticals (RYTM) to Release Earnings on Tuesday - MarketBeat
Rhythm Pharmaceuticals stock reaches all-time high at 114.04 USD By Investing.com - Investing.com Australia
Three Boston biotechs await FDA decisions on new drugs by year-end - The Business Journals
Published on: 2025-10-29 02:54:50 - newser.com
Rhythm Pharmaceuticals Inc Stock (RYTM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):